Centonze V, Bassi A, Causarano V, Dalfino L, Cassiano M A, Centonze A, Fabbri L, Albano O
Dept of Internal Medicine and Public Medicine, University of Bari, Italy.
Funct Neurol. 2000 Jul-Sep;15(3):167-70.
This observational study was designed to examine the pattern of sumatriptan use in patients with cluster headache using more than the recommended daily dose of subcutaneously injected (s.c.) sumatriptan. Thirteen patients suffering from episodic cluster headache were asked to record the characteristics of their attacks and drug intake for 1 year. All reported a high daily frequency of attacks (more than 3 per day) and the related overuse of s.c. sumatriptan. The results show that the overall incidence of adverse events among patients receiving sumatriptan injections for the treatment of cluster headache is low. The extended administration of this drug in episodic cluster headache did not result in tolerance problems or tachyphylaxis. Only 4 patients experienced minor adverse events and recovered more slowly than the others. They suffered from migraine without aura and cluster headache, and showed a family history of migraine. Even though they must be viewed with caution, due to the observational nature of the study and the low number of patients included, these results suggest that the profile of sumatriptan may differ in cluster headache compared with migraine.
这项观察性研究旨在调查使用超过皮下注射舒马曲坦推荐日剂量的丛集性头痛患者的舒马曲坦使用模式。13名发作性丛集性头痛患者被要求记录其发作特征和药物摄入情况，为期1年。所有患者均报告每日发作频率较高（每天超过3次）以及皮下注射舒马曲坦的相关过度使用情况。结果显示，接受舒马曲坦注射治疗丛集性头痛的患者中不良事件的总体发生率较低。在发作性丛集性头痛中延长使用这种药物并未导致耐受性问题或快速减敏。只有4名患者经历了轻微不良事件，且恢复比其他患者慢。他们患有无先兆偏头痛和丛集性头痛，并显示有偏头痛家族史。尽管由于研究的观察性质和纳入患者数量较少，必须谨慎看待这些结果，但这些结果表明，与偏头痛相比，舒马曲坦在丛集性头痛中的情况可能有所不同。
